Loading...
XSHE002688
Market cap424mUSD
Jan 09, Last price  
4.15CNY
1D
-0.95%
1Q
3.49%
Jan 2017
-58.91%
IPO
-24.95%
Name

Jinhe Biotechnology Co Ltd

Chart & Performance

D1W1MN
XSHE:002688 chart
P/E
35.97
P/S
1.43
EPS
0.12
Div Yield, %
4.78%
Shrs. gr., 5y
4.39%
Rev. gr., 5y
5.94%
Revenues
2.17b
+2.42%
444,386,448458,751,898590,218,256720,726,464770,405,139741,071,198839,805,8061,250,468,5331,495,686,2561,457,826,3591,628,890,0981,782,364,0811,814,638,9652,077,988,7302,122,705,3172,174,131,033
Net income
86m
-26.76%
15,869,57627,027,76352,753,94377,404,78889,576,88090,432,47077,209,555104,652,699164,129,151108,423,892163,628,881184,938,644117,324,52593,992,380118,040,48686,457,012
CFO
199m
+59.69%
11,637,20623,195,301118,049,223106,590,75488,806,099148,323,1430214,966,344292,411,55527,253,028117,174,643282,185,997258,079,960152,978,505124,471,194198,765,852
Dividend
May 31, 20240.1 CNY/sh

Profile

Jinhe Biotechnology CO., LTD. produces and sells veterinary medicines in China. The company offers chlortetracycline feed grade, an antimicrobial drug for the inhibition and treatment of white dysentery, enteritis, pneumonia, typhoid, paratyphoid, cholera, etc. in poultry and livestock; and chlortetracycline hydrochloride for the inhibition and treatment of pullorum disease, typhoid, and swine enteritis, as well as bacterial diseases, including paratyphoid and cholera. It also exports its products to the United States, South-east Asia, Latin America, Europe, etc. The company was founded in 1990 and is based in Dalian, China.
URL
http://www.jinhe.com.cn
IPO date
Jul 13, 2012
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,174,131
2.42%
2,122,705
2.15%
Cost of revenue
1,896,402
1,779,673
Unusual Expense (Income)
NOPBT
277,729
343,033
NOPBT Margin
12.77%
16.16%
Operating Taxes
7,062
804
Tax Rate
2.54%
0.23%
NOPAT
270,667
342,228
Net income
86,457
-26.76%
118,040
25.59%
Dividends
(148,694)
Dividend yield
3.96%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,686,703
1,297,818
Long-term debt
549,870
311,563
Deferred revenue
39,240
38,091
Other long-term liabilities
1
1
Net debt
1,616,287
1,114,861
Cash flow
Cash from operating activities
198,766
124,471
CAPEX
(457,217)
Cash from investing activities
(537,942)
Cash from financing activities
413,051
150,433
FCF
(136,170)
(70,779)
Balance
Cash
608,638
491,368
Long term investments
11,648
3,151
Excess cash
511,580
388,384
Stockholders' equity
1,780,395
1,688,930
Invested Capital
4,254,725
3,667,281
ROIC
6.83%
9.79%
ROCE
5.69%
8.31%
EV
Common stock shares outstanding
780,298
780,407
Price
4.81
-6.42%
5.14
-16.15%
Market cap
3,753,234
-6.43%
4,011,290
-2.53%
EV
5,639,411
5,329,778
EBITDA
458,659
498,928
EV/EBITDA
12.30
10.68
Interest
60,175
46,562
Interest/NOPBT
21.67%
13.57%